Technical Analysis for ATRA - Atara Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -2.82% | |
| Wide Bands | Range Expansion | -2.82% |
| Alert | Time |
|---|---|
| Down 2 % | about 22 hours ago |
| Down 1% | about 22 hours ago |
| Up 1% | about 22 hours ago |
| Down 3% | 2 days ago |
| 10 DMA Resistance | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.5 |
| 52 Week Low | 6.5 |
| Average Volume | 115,522 |
| 200-Day Moving Average | 12.56 |
| 50-Day Moving Average | 9.14 |
| 20-Day Moving Average | 10.59 |
| 10-Day Moving Average | 11.69 |
| Average True Range | 1.19 |
| RSI (14) | 51.46 |
| ADX | 41.24 |
| +DI | 30.58 |
| -DI | 17.54 |
| Chandelier Exit (Long, 3 ATRs) | 11.36 |
| Chandelier Exit (Short, 3 ATRs) | 11.81 |
| Upper Bollinger Bands | 13.59 |
| Lower Bollinger Band | 7.59 |
| Percent B (%b) | 0.52 |
| BandWidth | 56.63 |
| MACD Line | 0.77 |
| MACD Signal Line | 0.84 |
| MACD Histogram | -0.0702 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.93 | ||||
| Resistance 3 (R3) | 11.94 | 11.55 | 11.72 | ||
| Resistance 2 (R2) | 11.55 | 11.23 | 11.54 | 11.65 | |
| Resistance 1 (R1) | 11.11 | 11.03 | 10.92 | 11.10 | 11.58 |
| Pivot Point | 10.72 | 10.72 | 10.62 | 10.71 | 10.72 |
| Support 1 (S1) | 10.28 | 10.40 | 10.09 | 10.27 | 9.78 |
| Support 2 (S2) | 9.89 | 10.20 | 9.88 | 9.71 | |
| Support 3 (S3) | 9.45 | 9.89 | 9.64 | ||
| Support 4 (S4) | 9.44 |
